Navigation Links
Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting

BETHESDA, Md.--(BUSINESS WIRE)--May 7, 2007 - REGENERX BIOPHARMACEUTICALS' (AMEX: RGN), www.regenerx.com - Dr. Gabriel Sosne will be speaking at the 2007 Association for Research in Vision and Ophthalmology (ARVO) meeting in Ft. Lauderdale, Florida on May 9th to discuss TB4's ability to inhibit corneal neutrophil infiltration. Neutrophil infiltration is a process closely associated with inflammation that, if not properly controlled, can cause substantial tissue and organ damage. According to Dr. Sosne, TB4 inhibits neutrophil infiltration by decreasing and/or suppressing the expression of several different types of inflammatory molecules, some of which have been previously identified and the subject of several ophthalmic publications.

"The importance of this finding is that it gives us a better understanding of the pathway TB4 uses to reduce inflammation and increases the clinical relevance of TB4 as we translate the work from the laboratory bench into patients. Our understanding of the neutrophil connection applies not only to TB4's mechanism of action in eye wounds, but likely also at organ and tissue sites such as the skin and heart, among others," said Dr. Sosne, Assistant Professor of Ophthalmology at Wayne State University and the Kresge Eye Institute in Detroit, Michigan.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore, RegeneRx is developing TB4 as the cornerstone of its therapeutic platform. The technology platform has many potential applications in both the pharmaceutical and consumer products sectors. RegeneRx holds nearly 60 world-wide paten
'"/>




Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gabriel Sosne Present New Data ARVO Meeting
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... WOODCLIFF LAKE, N.J. and STAMFORD, ... the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and ... into a worldwide collaboration agreement for the development and ... a dual orexin receptor antagonist entering Phase III clinical ... Under the terms of the agreement, Eisai and Purdue ...
(Date:8/31/2015)... Australia , Aug. 31, 2015 Bionomics ... discovery and development of innovative therapeutics for the treatment ... cancer, today announced that its BNC101 IND submission has ... (FDA). Bionomics plans to initiate a Phase 1 clinical ... patients with metastatic pancreatic cancer prior to 31 December ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and ... labels and stickers to keep little ones' safety top of mind at all times. ... a particular focus. According to the JPMA's Baby Safety Zone website, this year's theme ...
(Date:9/1/2015)... ... 2015 , ... Curly Hair Solutions™ is thrilled to partner ... partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution of ... Curly Hair Solutions™ team could not be more delighted to see their line ...
(Date:8/31/2015)... ... 01, 2015 , ... Spinal fusion surgery – which connects ... long, arduous recovery. However, today’s minimally invasive fusions achieve similar results as traditional ... muscle damage. These advantages of minimally invasive surgery redeem the procedure’s reputation, according ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... potential patients the resources they need to have a successful cosmetic procedure; from ... plastic surgeons; Cosmetic Town Journal is always ready to help. , It is ...
(Date:8/31/2015)... ... , ... Southern Vacation Rentals – a member of the locally owned and ... property management company, 360 Blue, in support of the Sonder Project, a global ... two companies will collect any unopened food items left in vacation rentals after guest ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3
... (May 12, 2008) The Virginia Commonwealth University School ... $6 million from the National Institutes of Healths National ... polycystic ovary syndrome, a disorder of the endocrine system ... Polycystic ovary syndrome, or PCOS, causes hormonal imbalances leading ...
... impact and other influences are limiting the growth ... of frequency and severity of ... AOC ),the leading provider of global risk management and consulting ... care industry,finding for the first time in nine years of ...
... ... oxide material., DENVER, May 12 C5 Medical Werks, ... has submitted a 510(k),pre-market notification to the U.S. Food and ... CAD/CAM Blocks.,ZirDent(TM) is a zirconium material ideally suited to meet ...
... proposals, to expand oral health care services; awards two significant oral ... ... 12 As part of the Illinois,Children,s Healthcare Foundation,s (ILCHF) $20 million, ... is pleased to announce a request for proposals in the oral,health care ...
... games throughout the ... region, PHILADELPHIA, May ... cosponsor the Senior Games, held at,dozens of locations throughout the five-county Philadelphia region. ... each,county, beginning Monday, May 12 and continuing through the month of June.,More than ...
... trial in bladder cancer exceeds 2/3rds enrolment level ... pre-clinical work in peritoneal cancers -, BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, is ... non-clinical development of its proprietary platform technology:,Mycobacterial Cell ...
Cached Medicine News:Health News:NIH grant to support Translational Research Center for PCOS 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 3Health News:C5 Medical Werks Applies for Clearance, Certification and Licensing for the Global Marketing of ZirDent(TM) Ceramic CAD/CAM Dental Blocks 2Health News:Children in Illinois to Have Healthier Smiles 2Health News:Independence Blue Cross Supports 2008 Senior Games 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 3Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 4
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: